Diamyd Medical AB Granted Orphan Drug Designation in the US
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: The FDA has granted Orphan Drug Designation of Diamyd Medical´s lead drug candidate Diamyd®. Orphan drugs qualify for seven years of market exclusivity from the date of US marketing approval, tax credits for clinical research and a waiver for FDA user fees.